# CoRegen

> CoRegen, Inc. (CoRegen Science) is a clinical-stage biopharmaceutical company in Houston, Texas developing CRISPR-engineered regulatory T (Treg) cell therapies for aggressive solid tumors, built on SRC-3 steroid receptor coactivator science licensed exclusively from the O'Malley Lab at Baylor College of Medicine. CoRegen publishes **no API, SDK, developer portal, or machine-readable specification**. This file is generated by API Evangelist from its public website; it is not published by CoRegen.

<!--
generated: '2026-08-11'
method: generated
source: apis.yml + https://www.coregen.com/ (searched https://www.coregen.com/llms.txt -> HTTP 404)
-->

## APIs

- No public API surface. On `www.coregen.com`, `/api`, `/api/v1`, `/developers`, `/developer`, `/docs`, `/graphql`, `/mcp`, `/openapi.json`, `/swagger.json`, `/api-docs` and `/llms.txt` all return HTTP 404 (a control probe of a nonsense path also returns 404, so these are genuine misses, not a soft-404 catch-all). Every `/.well-known/*` path returns a hard HTTP 400 Wix error page. `api.coregen.com`, `developer.coregen.com`, `docs.coregen.com`, `dev.coregen.com`, `portal.coregen.com`, `mcp.coregen.com` and `agent.coregen.com` do not resolve in DNS (checked 2026-08-11).
- Note on identity: the GitHub organization `github.com/coregen` ("Devops, one principle at a time", coregen.io) is a **different, unrelated company** and is deliberately not linked from this profile.

## Science

- [The Science](https://www.coregen.com/thescience): Knocking out the SRC-3 gene in regulatory T (Treg) cells reprograms them from immunosuppressors into tumor-killing effectors; SRC family coactivators are the "master regulators" of gene function, researched by the O'Malley Lab at Baylor College of Medicine since the 1970s.
- [Preclinical Studies](https://www.coregen.com/preclinicalstudies): Preclinical results in tumor-bearing mice, reported by the company as eradication and prevention of tumors without observed toxicity or inflammation.
- [Pipeline](https://www.coregen.com/pipeline): Development programs, including CRG-150, an autologous CRISPR-engineered Treg cell therapy for advanced solid tumors.
- [Publications](https://www.coregen.com/publications): Peer-reviewed publications underpinning the platform; the 2023 Cozzarelli Prize was awarded for the company's founding science.

## Company

- [Website](https://www.coregen.com/)
- [About](https://www.coregen.com/about)
- [Leadership](https://www.coregen.com/leadership)
- [News](https://www.coregen.com/news)
- [Careers](https://www.coregen.com/careers)
- [Contact](https://www.coregen.com/contact) — CoRegen, Inc., Houston, TX 77002

## Artifacts

- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/coregen/refs/heads/main/security/coregen-domain-security.yml): TLS/HSTS/DNSSEC/CAA/SPF/DMARC posture for coregen.com, probed by API Evangelist.
- [Well-known probe](https://raw.githubusercontent.com/api-evangelist/coregen/refs/heads/main/well-known/coregen-well-known.yml): recorded absence of every `/.well-known/*` discovery document.

## Optional

- [Terms & Conditions](https://www.coregen.com/terms-and-conditions)
- [Privacy Policy](https://www.coregen.com/privacy-policy)
- [Forge Global secondary-market listing](https://forgeglobal.com/coregen_stock/)